GenScript Biotech Corporation, a Cayman Islands-incorporated company, announced the grant of Restricted Shares under its 2021 RSA Scheme. On June 11, 2025, the company awarded a total of 6,777,120 Restricted Shares. Among these, 6,707,292 shares were allocated to certain employees, while 69,828 shares were granted to two individual consultants engaged in technical research and strategic advisory services. This announcement highlights the company's ongoing efforts to reward and align key personnel with its growth objectives. The restricted shares were granted at no purchase price.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。